Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis by unknown
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Yttrium-90 microsphere radioembolization




either glass- or resin-based, is in-
creasingly applied in patients with
unresectable liver malignancies. Clin-
ical results are promising but overall
response and survival are not yet
known. Therefore a meta-analysis on
tumor response and survival in patients
who underwent 90Y-RE was con-
ducted. Based on an extensive litera-
ture search, six groups were formed.
Determinants were cancer type, mi-
crosphere type, chemotherapy protocol
used, and stage (deployment in first-
line or as salvage therapy). For colo-
rectal liver metastases (mCRC), in a
salvage setting, response was 79% for
90Y-RE combined with 5-fluorouracil/
leucovorin (5-FU/LV), and 79% when
combined with 5-FU/LV/oxaliplatin or
5-FU/LV/irinotecan, and in a first-line
setting 91% and 91%, respectively.
For hepatocellular carcinoma (HCC),
response was 89% for resin micro-
spheres and 78% for glass micro-
spheres. No statistical method is
available to assess median survival
based on data presented in the litera-
ture. In mCRC, 90Y-RE delivers high
response rates, especially if used neo-
adjuvant to chemotherapy. In HCC,
90Y-RE with resin microspheres is
significantly more effective than
90Y-RE with glass microspheres. The
impact on survival will become known
only when the results of phase III
studies are published.
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Introduction
Internal radiation therapy through transarterial delivery of
beta-emitting yttrium-90 (90Y)-loaded microspheres, often
referred to as 90Y radioembolization (90Y-RE), is an
emerging technique for the treatment of patients with
unresectable primary or metastatic liver tumors [1, 2]. The
efficacy of this radioembolization technique is based on the
fact that intrahepatic malignancies derive their blood
supply almost entirely from the hepatic artery, as opposed
to the normal liver, which mainly depends on the portal
vein for its blood supply [3]. The microspheres are injected
selectively into the proper hepatic artery and subsequently
become lodged in the microvasculature surrounding the
tumor. Very high irradiation doses are delivered to the
tumors, whereas the surrounding liver parenchyma is
largely spared [4].
Two FDA-approved 90Y microsphere products are in
clinical use at present: TheraSphere® (MDS Nordion Inc.,
Kanata, Ontario, Canada), which are glass microspheres,
and the resin-based SIR-Spheres® (SIRTeX Medical Ltd.,
Sydney, New South Wales, Australia) (Table 1). The glass
microspheres are approved for use in radiation treatment or
as a neoadjuvant to surgery or transplantation in patients
with hepatocellular carcinoma (HCC). The resin micro-
spheres have FDA premarket approval for the treatment of
hepatic metastatic colorectal cancer (mCRC), with adju-
vant hepatic arterial infusion of floxuridine. However,
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patients suffering from other liver dominant cancers have
also undergone therapy with these 90Y microspheres. These
include, among others, liver metastases of breast cancer,
pancreatic cancer, and neuroendocrine tumors [5, 6]. Since in
most studies that have been published themajority of patients
underwent 90Y-RE in a salvage setting, and most of the
literature comprised phase I and II studies with small patient
numbers, the overall response and real impact on survival are
not known. In order to assess the effect of 90Y-RE for primary
and secondary liver malignancies, a systematic meta-anal-
ysis has been performed of the available literature.
Methods
Identification of studies
A comprehensive search was carried out using several
databases in order to identify relevant studies from 1986
onwards. The following search strategy was used to search
the MEDLINE database with PubMed: (“yttrium” [MeSH
Terms] OR yttrium [Text Word]) AND (“liver” [MeSH
Terms] OR liver [Text Word]). The limit “humans” was
used. The EMBASE database was searched with the limit
human using: (“yttrium”/exp OR “yttrium”) AND (“liver”/
exp OR “liver”). The Cochrane library database was
searched with the keywords “yttrium” and “liver”. The
search was completed by searching the reference lists and
related articles of all relevant articles found. In addition, the
reference lists of two presentations given at a workshop
held in Chicago 4–5 May 2007 [7] and the list of
publications in the clinicians’ section of the webpage of
SIRTeX Medical Ltd. [8] and the Resource Library on the
webpage of MDS Nordion Inc. [9] were screened.
Inclusion and exclusion criteria
All abstracts of relevant studies were reviewed with a set of
predefined inclusion and exclusion criteria. All articles
from 1986 onwards which presented data concerning
tumor response or survival of patients with primary or
secondary liver malignancies after treatment with 90Y glass
or 90Y resin microspheres were included for further data
extraction. This resulted in 44 articles (Fig. 1). Articles
written in a language other than English or German were
excluded; articles that presented data that were thought to
have been presented previously were used once. Conse-
quently, one article was excluded because it was written in
Chinese, and another was excluded, since it was thought to
present data that were also presented in another larger trial.
This resulted in 42 articles from which data were extracted.
Data extraction
After the initial assessment for inclusion the following data
were extracted from the 42 articles selected: study design,
number, and demographic data of patients; minor extrahe-
patic disease included/excluded, previous therapies tar-
geted on the liver tumor, administered dosage, site of
microsphere delivery, use of angiotensin II, number of
microsphere treatments, (neo)adjuvant therapies, tumor
response measured by CT, MRI, and/or 18F-FDG-PET,
serum markers measurements (CEA, AFP), time to
progression, and survival.
After initial data extraction, the exclusion criteria were
reassessed. It became clear that most studies presented
adequate data on patients with HCC or with mCRC, and
that response was usually measured by CT. The meta-
analysis was therefore limited to these two tumor types. In
order to perform a meta-analysis, additional exclusion
criteria were incorporated. Articles that did not present data
about HCC and/or mCRC and articles only presenting data
on groups with mixed primary disease were excluded from
the meta-analysis. Articles that did not present tumor
response measured by CT scans or that did not present data
on median survival times were also excluded. Following
the additional exclusion criteria, an additional 12 articles
were excluded from the meta-analysis.
Table 1 Yttrium-90 microsphere products characteristics

































3.9 Glass 3.3 25±10 110b 4,000,000 5,000 1,250b–2,500
SIR-Spheres®
(SIRTeX Ltd.)
Resin 1.6 32±10 1,370b 50,000,000 3,000 50b




The 30 remaining articles were divided into two groups,
according to tumor type, i.e., mCRC or HCC. The
pathology of these two types of liver tumors is very
different. Colorectal carcinoma initially metastasizes to one
or a few focal parts of the liver, whereas HCC usually
spreads diffusely throughout the liver. Response to
chemotherapy is also very different in these tumor types.
This resulted in the formation of two groups (mCRC and
HCC), for which the studies were compared on design and
patient population, in order to assess the comparability of
the results.
In the group of patients with mCRC, after data extraction
the use of different (generations of) chemotherapy regi-
mens was identified as a major source of heterogeneity.
Two covariates were therefore included in the meta-
regression model: (1) whether the older generation of
cytostatic agents (5-FU/LV or floxuridine) or the newer
generation (5-FU/LV + oxaliplatin (FOLFOX) or 5-FU/LV
+ irinotecan (FOLFIRI)) was used, and (2) whether 90Y-RE
was given as a salvage therapy or as a first-line treatment
with adjuvant chemotherapy. No separation was made
between the microsphere product that was used (glass or
resin), because of the small number of patients with mCRC
treated with the glass microspheres (ca. 8%).
In view of the chemoresistant nature of HCC [10],
previously given therapy was not observed as a source of
heterogeneity. Therefore, the main source of heterogeneity
observed in this group was the microsphere product used,
either glass or resin. This resulted in the formation of two
subgroups.
To allow comparability of results with regard to tumor
response, the category of ‘any response’ (AR) was
Search in MEDLINE, EMBASE and Cochrane library 
Inclusion criteria 
Patients with primary  
or 
secondary liver  
malignancies 
and 
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739 articles 
Screening related articles and references.  
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Additional excluded articles 
2 only patients with breast cancer  
4 no tumor response on CT and no survival presented 
5 outcomes not apart for HCC and mCRC 
1 outcome not apart for resin and glass microspheres 
 
Fig. 1 Flowchart summarizing the selection of relevant articles
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introduced. The AR category comprises all patients
originally from the categories complete response, partial
response, and stable disease.
Meta-analysis
The study of Andrews et al. [11] included just one HCC
patient. This patient was therefore not included in the
analysis. The proportions of patients with AR were
modeled by a meta-regression analysis according to
Hamza et al. [12]. This method uses the exact binomial
likelihood approach instead of an approximate method
based on the normal distribution of within-study variability.
A random effects model was applied since considerable
heterogeneity was observed between the studies. The meta-
regression analysis was performed using PROCNLMIXED
in SAS version 9.1 as described by Hamza et al.
Results
Thirty articles were included in the meta-analysis. In 999
out of 1,217 patients, tumor response was assessed by CT.
The proportion of AR for HCC and mCRC combined
varied between 0.29 and 1.00 with a median value of 0.82.
Treatment with glass microspheres showed a lower
response (AR=0.77) than treatment with resin micro-
spheres (AR=0.85) (p=0.07), with an estimated odds ratio
of 0.56 (95% CI 0.29–1.06).
Colorectal liver metastases
In a total of 19 eligible studies 792 patients with mCRC had
undergone 90Y-RE [6, 11, 13–29]. In 18 studies tumor
response was assessed in a total of 681 patients. Of these
patients 486/681 had received 90Y-RE in a salvage setting,
of which 124/486 had been previously treated and/or co-
treated with 5-FU/LVor floxuridine, and 362/486 had been
given the newer-generation cytostatic agents. One hundred
and ninety-five patients had received 90Y-RE as a first-line
treatment, of which 175/195 were treated with adjuvant 5-
FU/LV or floxuridine and 20/195 with FOLFOX.
The specific cytostatic agent(s) (“old” versus “new”) that
were used did not affect response (p=0.96).Whether 90Y-RE
was offered in a salvage setting or as a first-line therapy
affected tumor response significantly (p=0.07). The esti-
mated proportions of AR, based on the regression model,
were 0.79 and 0.79 in salvage setting and 0.91 and 0.91 in the
first-line, for the older and newer chemotherapy, respectively.
Median survival after 90Y-RE, irrespective of differences
in determinants (microspheres type, chemotherapy proto-
col, and stage: salvage or first-line), varied from 6.7 to
17.0 months. The reported median survival from diagnosis
of mCRC ranged from 10.8 to 29.4 months (Table 2).
Two randomized controlled trials were performed in
patients with unresectable mCRC. In 2001, Gray et al.
presented the results for 76 patients who had been
randomized to either 90Y-RE (resin) as neoadjuvant to
hepatic arterial infusion (HAI) of floxuridine or to HAI
alone [14]. Patients in the combination arm showed a
significantly greater response when measured by tumor
volume, and a significantly increased time to progression.
AR was 78% and 59% (p=0.03) for the combination arm
and the HAI-alone arm, respectively, and time to progres-
sion, based on tumor area measurements, was 15.9 months
vs. 9.7 months (p=0.001), respectively. In 2004, Van Hazel
et al. reported on the outcome in 21 previously untreated
patients with mCRC [15] in a similar study, in which it was
demonstrated that the addition of a single administration of
resin microspheres prior to 5-FU/LV significantly in-
creased response, time to progression, and survival. In this
phase II trial AR was 100% in the combination arm vs.
60% in the chemotherapy-alone arm (p<0.001), time to
progression 18.6 and 3.6 months (p<0.0005), respectively,
and survival 29.4 and 12.8 months (p=0.02). Thirty-six
months postrandomization 36% of patients in the combina-
tion arm were still alive, whereas no patients from the 5-
FU/LV-alone arm were alive at that time.
Hepatocellular carcinoma
In 14 articles clinical data were presented on tumor
response and survival for 425 patients with HCC who had
received 90Y-RE [11, 18, 24, 30–40]. Twelve studies
presented data of tumor response for a total of 318 patients.
Treatment with resin microspheres was associated with a
significantly higher proportion of AR than glass micro-
sphere treatment (0.89 vs. 0.78 (p=0.02)).
Median survival was reported in seven studies in which
survival time was defined as survival from treatment or
from diagnosis or recurrence. Median survival from
microsphere treatment varied between 7.1 and 21.0 months,
and median survival from diagnosis or recurrence was 9.4–
24.0 months (Table 3).
Discussion
This meta-analysis showed that in patients with mCRC the
tumor response of 90Y-RE is high, with AR rates of
approximately 80% in a salvage setting, and over 90%
when used as first-line treatment, as neoadjuvant to chemo-
therapy. The response rates reported for studies inwhich 5FU/
LV was combined with irinotecan or oxaliplatin were similar
to those of studies in which only 5FU/LV was used. This can
probably be explained by differences in the criteria for tumor
response that were used (WHO versus RECISTcriteria [41]).
Regarding the question as to which microsphere is most
effective in the treatment of mCRC—glass or resin—no
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conclusions can be reached since only 8% of the patients
with mCRC were treated with the glass microspheres.
Furthermore, the meta-analysis showed that resin micro-
spheres were significantly more effective in treating HCC
than glass microspheres (AR 89% vs. 78% (p=0.02)). This
is a rather unexpected finding, because only the glass
microspheres are FDA-approved for treating HCC,
whereas the resin microspheres are approved for mCRC,
not HCC. It may be postulated that this outcome is the
consequence of the substantial difference in numbers of
microspheres that are infused: a dose of glass microspheres
consists of 4 million microspheres, whereas a dose of resin
microspheres usually contains 50 million microspheres
[42]. It has been reported in the literature that administra-
tion of resin microspheres had to be prematurely halted,
before the predetermined amount of radioactivity was
instilled, due to macroscopic embolization [43]. In contrast,
the relatively very low number of glass microspheres per
dose is associated with microscopic embolization [39].
However, the low number of particles infused in the case of
the glass microspheres may be a disadvantage when
targeting a tumor type that is often diffusely spread
throughout the liver at the time of diagnosis [44]; the
radiation dose would be distributed in and around the
tumors too heterogeneously to be able to deliver a
tumoricidal dose to the entire lesion even if the total


























Gray et al. (1992) [13] 29 22 3 – 0 45 37 82 18 NR NR
Stubbs et al. (1999) [29] 30 27 3 – 0 70 19 89 11 10.8 (range
1.9–41.0)
6.7 (range 1.0–15.8)
Gray et al. (2000) [28] 71 51 3 – 0 75 12 86 14 17.3 9.9
Gray et al. (2001)b [14] 36 36c 3 – 6 44 28 78 14 NR 17.0
Stubbs et al. (2001) [16] 50 44 3 – 0 73 18 91 9 14.5 (range
1.9–91.4)
9.8 (range 1.0–30.3)
Van Hazel et al. (2004)b [15] 11 11 3 Yes 0 91 9 100 0 29.4 NR
Lim et al. (2005) [18] 30 30 2 Yes 0 33 27 60 40 NR NR
Lim et al. (2005) [19] 32 32 2 Yes 0 31 28 59 41 NR NR
Murthy et al. (2005) [17] 12 9 NR Yes 0 0 56 56 44 24.6 4.5
Mancini et al. (2006) [20] 35 35 1.5 Yes 0 12 76 88 13 NR NR
Kennedy et al. (2006) [21] 208 208 3 – 0 36 55 91 10 NR Responders 10.5
Non-responders 4.5
Stubbs et al. (2006) [22] 100 80 3 – 1 73 20 94 6 16.2 (range
1.1–101.6)
11 (range 0.1–76.6)
Jakobs et al. (2007) [24] 18 18 2–3 – 0 NS NS 76 24 NR NR
Sharma et al. (2007) [23] 20 20 3 Yes 0 90 10 100 0 NR NR
Glass microspheres
Anderson et al. (1992) [25] 7 7 2 – 0 0 86 86 14 NR 11 (range 5–25+)
Andrews et al. (1994) [11] 17 17 2 – 0 29 29 59 41 NR 13.8
Wong et al. (2002) [26] 8 8 3 – 12 12 38 63 38 NR NR
Lewandowski et al. (2005) [27] 27 26 3 – 0 35 52 87 13 NR 9.3 (95% CI 7.2–13.3)
Sato et al. (2008) [6] 51 51 5.3 – NR NR NR NR NR NR 15.2
CR complete response, PR partial response, SD stable disease, AR any response (= CR + PR + SD), PD progressive disease, NR not reported,
NS not specified
aResponse measured and presented according to RECIST criteria [41]
bResponse and survival for 90Y-RE arm alone
cCT of 3 out of 36 patients not assessable
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amount of radioactivity of a dose of glass microspheres is
at least 50% higher than is the case in the resin
microspheres (Table 1). Another (theoretical) consideration
is that the macroembolic effect of the resin microspheres is
accompanied by a greater lack of oxygen resulting in
ischemia and therefore enhanced efficacy. On the other
hand, shortage of oxygen might also diminish the tumor-
icidal effect of ionizing radiation due to a lack of oxygen
radicals that is produced in this environment.
However, this macroembolic effect can be associated
with clinical signs, the so-called postembolization syn-
drome (PES), which is reported to frequently occur
following resin microspheres infusion, but not often
subsequent to administration of the minimally embolic
glass microspheres. PES is characterized by fatigue,
nausea, fever, right upper quadrant pain, and/or vomitus,
all of which are transitory and can be effectively controlled
by outpatient medication [21, 39, 45–47].
Serious complications have been reported when micro-
spheres were inadvertently deposited in excessive amounts
in organs other than the liver. Conditions that have been
reported include gastrointestinal ulceration/bleeding, gas-
tritis/duodenitis, cholecystitis, pancreatitis, and radiation
pneumonitis [42, 45, 48–52]. Training, careful patient
selection, meticulous pretreatment assessment, and coiling
of relevant vasculature reduce complication rates mas-
sively [53]. Radiation-induced liver disease following 90Y-
RE has been reported sporadically [15, 54]. Careful patient
selection and individualized dose calculation minimize the
risk of this complication. Profound and persistent lympho-



























Lau et al. (1994) [31] 18 18 2 – 0 44 44 89 11 NR 7.1
Lau et al. (1998) [32] 71 71 2 – 0 27 65 92 8 9.4 (range
1.8–46.4)
NR
Lim et al. (2005) [19] 5 4 2 Yes 0 25 50 75 25 NR NR
Sangro et al. (2006) [33] 24 21 2 – NS NS NS 88 12 NR 7.1 (95%
CI 2.1–12)
Jakobs et al. (2007) [24] 5 5 2–3 Yes 0 NS NS 100 0 NR NR
Glass microspheres
Houle et al. (1989) [34] 7 7 NR – 0 0 29 29 71 NR NR
Andrews et al. (1994) [11] 1 1 2 – 0 0 0 0 100 NR NR
Dancey et al. (2000) [35] 22 19 2–3 – 5 16 58 79 21 NR 12 (range 2–42)





Geschwind et al. (2004) [30] 100 NR NR NR NR NR NR NR NR NR Okuda I 21.0
Okuda II 1.0
Liu et al. (2004) [37] 11 11 1–1.5 – 9 72 0 82 18 NR NR





Kulik et al. (2006) [40] 35 34 6 (0.8–16) – NS NS NS 88 12 NR NR
Sato et al. (2006) [39] 19 19 5 (1.5–14) – NS NS NS 79 21 NR NR
CR complete response, PR partial response, SD stable disease, AR any response (= CR + PR + SD), PD progressive disease, NR not reported,
NS not specified
aResponse measured and presented according to RECIST criteria [41]
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penia, with rapid onset and in some cases lasting over
12 months, though without clinical consequences, has been
reported in patients with HCC following 90Y-RE with glass
microspheres [36, 38]. This complication has not been
observed subsequent to 90Y-RE with resin microspheres (as
monotherapy). The underlying mechanism is not clear but
myelosuppression is not probable since leaching of radio-
activity from the glass microspheres does not take place
[55]. However, following 90Y-RE, in addition to the liver
tumors and to some extent the liver parenchyma, a radiation
dose is delivered to the blood each time it passes the liver,
which might explain this adverse laboratory event.
Unfortunately, in this meta-analysis overall tumor
response could only be assessed as ‘any response’, which
is caused by the reality that response categories were not
uniformly defined in the analyzed studies. It is expected
that this problem of being able to compare tumor response
will disappear in the near future, since the RECIST criteria,
published in 2001 [41], are evermore applied. In
accordance with the RECIST criteria, tumor response in
malignant liver disease is assessed using cross-sectional
anatomic imaging (CT, MRI), by measuring tumor size.
However, lesion size reduction does not always occur even
if treatment is effective. This is associated with different
peri- and endotumoral processes that can occur post 90Y-
RE, e.g., peritumoral edema and hemorrhage, and ring
enhancement [56]. Therefore, actual tumor response may
often be better than is reported, based on CT measurements
alone. In a significant number of cases ‘stable disease’
could actually be minor, partial, or even complete response.
In order to improve sensitivity in assessing tumor response,
it is therefore strongly recommended that 18F-FDG-PET or
functional MRI (diffusion-weighted MRI) is added to post-
treatment response assessment protocols [56–59].
Only two randomized controlled trials were found in the
literature, both on resin microspheres and mCRC. The
results were encouraging, showing a major survival benefit
for the 90Y-RE + chemo arm. However, since then larger
controlled trials have commenced, in which more effective
chemotherapeutics were used [60].
In this paper the emphasis was placed on 90Y-RE in
patients with unresectable HCC and mCRC. Nonetheless,
patients with liver metastases from primaries other than
mCRC have been treated with 90Y-RE. This is particularly the
case for liver metastasized breast cancer, of which response
rates of over 90% are reported [61, 62]. 90Y-RE has been
applied in patients with neuroendocrine liver metastases, too,
albeit in small numbers [11, 63]. Reported response rates
were 100%, and it would therefore be worthwhile to further
explore the use of 90Y-RE for this indication.
Fortunately, 90Y-RE is not the only novel and effective
treatment option offered to patients with unresectable
HCC. Recently, a breakthrough has been reported in the
field of biological agents. For sorafenib (Nexavar®, Bayer
Healtcare AG, Leverkusen, Germany), an oral multikinase
inhibitor, a statistically significant and clinically mean-
ingful improvement in survival has been shown in HCC
patients with advanced disease: 10.7 months in the
sorafenib group versus 7.9 months in the placebo group
(p=0.0006) [64]. Recently, a phase I/II trial has started in
which patients with unresectable HCC are treated with the
resin microspheres plus sorafenib [60].
The clinical efficacy of other promising molecular
agents, e.g., bevacizumab, erlotinib, is currently being
investigated as well. When added to FOLFOX or XELOX
(capecitabine + oxaliplatin), the angiogenesis inhibitor
bevacizumab (Avastin®, Genentech Inc., South San
Francisco, CA, USA) has been proven to prolong survival
of patients with colorectal cancer by approximately
6 months compared with FOLFOX or XELOX alone [65,
66]. In fact, in an ongoing multicenter study, the “FAST”
trial, patients with unresectable colorectal liver metastases
are treated concurrently with FOLFOX or FOLFIRI,
bevacizumab, and 90Y-RE (resin microspheres) [67].
In conclusion, 90Y-RE is associated with high response
rates, both in a salvage and in a first-line setting. The true
impact on survival will only become known after
publication of several ongoing and/or to be initiated
phase III studies. The results of trials in which 90Y-RE
and modern chemotherapy agents are combined with novel
biological agents are awaited with interest as well.
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